IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
This study has been terminated.
(PI left institution.)
Sponsor:
New Mexico Cancer Care Alliance
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance
ClinicalTrials.gov Identifier:
NCT00391586
First received: October 23, 2006
Last updated: August 14, 2015
Last verified: August 2015
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study was conducted to compare the activities of erlotinib to that of intravenous, platinum-based therapy in the treatment of non-small cell lung cancer (NSCLC). The goal of this trial was to demonstrate clinical equivalence of erlotinib to platinum-based frontline therapy, compared to historical controls.
| Condition | Intervention | Phase |
|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Drug: Erlotinib Drug: Platinum-based chemotherapy | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung |
Resource links provided by NLM:
Genetics Home Reference related topics:
lung cancer
MedlinePlus related topics:
Lung Cancer
U.S. FDA Resources
Further study details as provided by New Mexico Cancer Care Alliance:
Primary Outcome Measures:
- Progression-free Survival (PFS) [ Time Frame: 5 years ]
- Toxicity Profile [ Time Frame: 28 days after last on-study treatment ]Toxicities are assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0. Toxicities are reported as the number of patients who experienced grade 3 or grade 4 adverse events after receiving at least one dose of on-study treatment.
| Enrollment: | 45 |
| Study Start Date: | July 2006 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Erlotinib followed by chemotherapy
Erlotinib: 150 mg orally once daily, Platinum-based chemotherapy regimen selections include: Carboplatin (Carbo) area under the curve (AUC) 6, or cisplatin (Cis) 60-100 mg/m2, day (D)1, administered with one of the following:
Carbo AUC 5-6, or Cis 60-100 mg/m2, D1, administered with one of the following:
Other regimens:
|
Drug: Erlotinib
Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months. Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient Other Names:
Drug: Platinum-based chemotherapy
Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
Other Names:
|
Detailed Description:
To compare the activities (the progression-free survival, the incidence and severity of toxicities, and reversibility of toxicities) of erlotinib to that of platinum-based therapy in NSCLC. A sequential therapy design has been chosen such that all patients will receive any potential benefits of both platinum-based and erlotinib therapy, without compromising survival by denying anyone potential therapy. With this design, progression-free survival will be tracked by treatment received. However, data will be generated which will show the safety and efficacy of erlotinib in the frontline setting (alone and with historical comparison to platinum-based therapy), as well as the potential safety and activity of platinum-based therapy in the "second-line" (post-erlotinib) setting. This should allow for the demonstration of the relative median time to progression, objective response and clinical benefit rates, overall survival, and safety and tolerability of erlotinib and platinum-based therapy in both the frontline and second-line settings in NSCLC. Also, in this fashion, the treatments serve as controls for each other, as well as being compared to historical controls; in the first line treatment portion, the platinum-based regimens serve as the historical control, while in the second-line setting, erlotinib serves as the historical control arm.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Prior chemotherapy will be allowed for other invasive malignancies, provided at least five years has elapsed since the completion of therapy and enrollment on this protocol. No prior chemotherapy for metastatic non-small cell lung cancer (NSCLC) will be allowed. Prior adjuvant or neoadjuvant chemotherapy for NSCLC will be allowed, provided at least six months have elapsed from the last dose of chemotherapy to the documentation of relapsed disease.
Baseline laboratory values (bone marrow, renal, hepatic):
-
Adequate bone marrow function:
- Absolute neutrophil count >1000/µL
- Platelet count >100'000/µL
-
Renal function:
- Serum creatinine < 2.0 mg %
-
Hepatic function:
- Bilirubin <1.5x normal
- Serum calcium < 12 mg/dl
Other Eligibility Criteria:
- Signed Informed Consent
- Eastern Cooperative Oncology Group (ECOG)/Zubrod/Southwest Oncology Group (SWOG) Performance Status <2 (Karnofsky Performance Status > 70%)
- Life expectancy > 8 weeks
- Male or female' age >18 years
- Patients of childbearing potential must be using an effective means of contraception.
- Histologic diagnosis of NSCLC that is advanced and cannot be treated adequately by radiotherapy or surgery; or metastatic disease
Exclusion Criteria:
- Prior therapy with an epidermal growth factor receptor inhibitor, including erlotinib, gefitinib, and cetuximab, as well as any investigational HER-1 inhibiting agent
- Pregnant or lactating females
- Myocardial infarction or ischemia within the 6 months before Cycle 0' Day 0
- Uncontrolled' clinically significant dysrhythmia
- History of prior malignancy within the prior five years, with the exception of non-melanoma carcinomas of the skin, and carcinoma in situ of the cervix
- Prior radiotherapy to an indicator lesion unless there is objective evidence of tumor growth in that lesion
- Uncontrolled metastatic disease of the central nervous system (previously treated, stable disease is allowable on this protocol)
- Radiotherapy within the 2 weeks before Cycle 1' Day 1
- Surgery within the 2 weeks before Cycle 1' Day 1
- Any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00391586
Please refer to this study by its ClinicalTrials.gov identifier: NCT00391586
Locations
| United States, New Mexico | |
| Lovelace Medical Group | |
| Albuquerque, New Mexico, United States, 87102 | |
| Hematology Oncology Associates NM | |
| Albuquerque, New Mexico, United States, 87106 | |
| Presbyterian Medical Group | |
| Albuquerque, New Mexico, United States, 87110 | |
| University of New Mexico Cancer Center | |
| Albuquerque, New Mexico, United States, 87131 | |
| New Mexico Cancer Care Associates | |
| Santa Fe, New Mexico, United States, 87505 | |
Sponsors and Collaborators
New Mexico Cancer Care Alliance
Genentech, Inc.
Investigators
| Principal Investigator: | Dennie V Jones, MD | University of New Mexico |
More Information
Additional Information:
| Responsible Party: | New Mexico Cancer Care Alliance |
| ClinicalTrials.gov Identifier: | NCT00391586 History of Changes |
| Other Study ID Numbers: |
INST 0601C NCI-2012-01264 ( Registry Identifier: NCI CTRP ) |
| Study First Received: | October 23, 2006 |
| Results First Received: | June 15, 2015 |
| Last Updated: | August 14, 2015 |
Keywords provided by New Mexico Cancer Care Alliance:
|
erlotinib NSCLC chemotherapy |
platinum lung lung cancer |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Non-Small-Cell Lung Lung Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Carcinoma, Bronchogenic Bronchial Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Paclitaxel Irinotecan |
Etoposide Vinorelbine Docetaxel Gemcitabine Etoposide phosphate Erlotinib Hydrochloride Pemetrexed Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites |
ClinicalTrials.gov processed this record on June 23, 2017